Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13501889 | 0.77 | DRD2 (0.41) | PIM1PIM3PIM2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL3549743 | 0.76 | DRD2 (0.40) | PIM1PIM3PIM2SLC6A2SLC6A4 | |
| SCHEMBL2280246 | 0.75 | HTR2A (0.41) | PIM1HTR2A | |
| SCHEMBL28947779 | 0.72 | SLC6A3 (0.43) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2A | |
| SCHEMBL12255443 | 0.71 | OPRM1 (0.40) | PIM1PIM3PIM2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL31412616 | 0.70 | SLC6A3 (0.42) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2A | |
| SCHEMBL26081968 | 0.70 | TSHR (0.33) | — | |
| SCHEMBL15819350 | 0.70 | HTR2A (0.59) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2A | |
| SCHEMBL21098104 | 0.69 | ADRA2A (0.34) | P2RX7 | |
| SCHEMBL3125944 | 0.68 | SLC6A3 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| WO-2010077624-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230498-A1 | BIARYL CARBOXAMIDES | PAFAH1B3, PAFAH1B2, FAAH2 | PIM1 4111/4885PIM3 3950/4885PIM2 3793/4885 |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | PAFAH1B3, PAFAH1B2, PAF1 | PIM1 3067/4885PIM3 3354/4885PIM2 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.